Eli Lilly's next-gen anti-obesity candidate hit it out of the park in a phase 3 study. This should help solidify the company's lead in this niche of the industry. Even after their strong run, Lilly's ...

Its lineup and pipeline put it well ahead of even its closest competitor. The drugmaker should continue riding this wave for the foreseeable future. Furthermore, Novo Nordisk is anticipating ...

Aktis Oncology (AKTS), a radiopharmaceutical drug developer backed by pharma giants such as Eli Lilly (LLY), has filed its preliminary regulatory filings with the Securities and Exchange Commission ...

What To Know: Novo Nordisk, one of Eli Lilly’s main competitors, announced a regulatory breakthrough for an oral weight loss drug. The FDA approved the company’s pill form of Wegovy, making it the ...

Eli Lilly (LLY) submitted an FDA application for orforglipron. The once-daily oral pill maintained weight loss after patients switched from injections. Lilly’s Zepbound achieved 20.2% average weight ...

In the latest weekly data update, Eli Lilly's quality score advanced from 89.66 to 90.04. This uptick pushes the stock into the “elite” tier of the market, ranking it higher than 90% of its peers.

Lily Collins was born into the entertainment world. She made her film debut in The Blind Side in 2009 and later earned a Golden Globe nomination for Warren Beatty’s Rules Don’t Apply in 2016. She went ...

Lily Tomlin has been a comedic talent for decades on film and television, but there's a lot more to the life and career of this icon than you might know. From her boundary-pushing relationship history ...

Behind the scenes, Lily Collins had a très magnifique new pal when filming the new season of “Emily in Paris”: her baby girl. The star of Netflix’s fashion-focused dramedy (now streaming its fifth ...

"Emily in Paris" season five is streaming now. Spoiler alert: If you haven't seen "Emily in Paris" season 5 yet, look away now. The new season of "Emily in Paris" is putting Emily and Mindy's ...

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the FDA for approval on Thursday. Eli Lilly’s LLY drug is called orforglipron.